Pediatric Praziquantel Consortium

Publication: Extrapolation of praziquantel pharmacokinetics to a pediatric population

03 October 2018

In September 2018, members of the Pediatric Praziquantel Consortium published a paper on the extrapolation of...

Performance Materials at Merck KGaA, Darmstadt, Germany: Key Player towards the success of the Consortium Pediatric Praziquantel Program

13 September 2018

The broad contribution by Merck KGaA, Darmstadt, Germany to the Pediatric Praziquantel Consortium includes the...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more